Back to discover
Disease

Malnutrition

Late-stage therapeutic developmentEmerging researchSteady momentum
8
Publications
20
Clinical trials
3
Related conditions
2023
Latest publication

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Mecaserminapproved

Approval — For the long-term treatment of growth failure in children and adolescents with severe pri… (2007)

Clinical trials

12 sponsors · 1 new · 1 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2007emaApprovalMecasermin· For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD). Severe primary IGFD is defined by: height standard deviation score ? -3.0 and; basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and; growth hormone (GH) sufficiency; exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

8 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20102023
Most influential
Major themes8
  • Malnutrition4
  • Sarcopenia2
  • Anorexia Nervosa1
  • Cognitive Dysfunction1
  • Deglutition Disorders1
  • Endocrinology1
  • Frailty1
  • Nervous System Diseases1
Leading journals4
  • Nutrients5
  • Hepatology (Baltimore, Md.)1
  • Metabolism: clinical and experimental1
  • Nutrition journal1
Leading researchers8
  • Agostini F1
  • Bernal W1
  • Bossi P1
  • Carey EJ1
  • Cortés-Albornoz MC1
  • Dasarathy S1
  • de Sire A1
  • de Sire R1
Affiliations (unnormalised)6
  • Cancer Treatment Centers of America® at Midwestern Regional Medical Center1
  • Clinical Nutrition and Dietetics Unit1
  • Copenhagen University Hospital (Rigshospitalet)1
  • Dental Clinic1
  • Department of Clinical Medicine and Surgery1
  • Dietetic and Clinical Nutrition Unit1

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Malnutrition is an imbalanced nutritional state caused by insufficient intake of nutrients to meet normal physiological requirements. The supplied literature treats it as a disturbance of nutritional status that can occur across settings, including oncology, aging, pregnancy, and eating disorders. It is discussed in relation to complications and epidemiology.

Causes

The grounding supports insufficient nutrient intake as the core cause of malnutrition. It also links malnutrition to inadequate maternal nutrient intake during pregnancy and to underweight states such as anorexia nervosa. In oncology and older adults, the literature describes tumor-related, treatment-related, age-related, and swallowing-related contributors to poor nutritional status.

Pathophysiology

The central biological feature is disrupted nutritional status due to inadequate nutrient availability for normal physiology. The literature associates malnutrition with downstream changes in body composition and function, including loss of muscle mass and strength in sarcopenia, endocrine changes in underweight states, and impaired swallowing in sarcopenic dysphagia. It is also linked to adverse outcomes such as poorer survival and other complications.

Risk factors

The supplied abstracts identify older age, cancer, diabetes, unresectable esophageal cancer, frailty, dysphagia, poor oral health, and pregnancy with inadequate nutrient intake as contexts associated with malnutrition or related nutritional decline. Tumor-related and treatment-related factors are also described as influencing nutritional status in oncology. The literature further notes underweight states and anorexia nervosa as relevant settings.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.